Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Jan 29:7:25.
doi: 10.1186/1475-2875-7-25.

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia

Affiliations
Case Reports

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia

Naawa Sipilanyambe et al. Malar J. .

Abstract

Background: Following the recognition that morbidity and mortality due to malaria had dramatically increased in the last three decades, in 2002 the government of Zambia reviewed its efforts to prevent and treat malaria. Convincing evidence of the failing efficacy of chloroquine resulted in the initiation of a process that eventually led to the development and implementation of a new national drug policy based on artemisinin-based combination therapy (ACT).

Methods: All published and unpublished documented evidence dealing with the antimalarial drug policy change was reviewed. These data were supplemented by the authors' observations of the policy change process. The information has been structured to capture the timing of events, the challenges encountered, and the resolutions reached in order to achieve implementation of the new treatment policy.

Results: A decision was made to change national drug policy to artemether-lumefantrine (AL) in the first quarter of 2002, with a formal announcement made in October 2002. During this period, efforts were undertaken to identify funding for the procurement of AL and to develop new malaria treatment guidelines, training materials, and plans for implementation of the policy. In order to avoid a delay in implementation, the policy change decision required a formal adoption within existing legislation. Starting with donated drug, a phased deployment of AL began in January 2003 with initial use in seven districts followed by scaling up to 28 districts in the second half of 2003 and then to all 72 districts countrywide in early 2004.

Conclusion: Drug policy changes are not without difficulties and demand a sustained international financing strategy for them to succeed. The Zambian experience demonstrates the need for a harmonized national consensus among many stakeholders and a political commitment to ensure that new policies are translated into practice quickly. To guarantee effective policies requires more effort and recognition that this becomes a health system and not a drug issue. This case study attempts to document the successful experience of change to ACT in Zambia and provides a realistic overview of some of the painful experiences and important lessons learnt.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timeline of the malaria drug policy change process in Zambia.

References

    1. Olumese PE. Global Antimalarial Drug Policy Database. Antimalarial treatment policies for P. falciparum and P. vivax by country in WHO African and Eastern Mediterranean region [April 2007 update] World Health Organization, Geneva, Switzerland; 2007. http://www.who.int/malaria/treatmentpolicies.html - PubMed
    1. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. Impact of chloroquine resistance on malaria mortality. Comptes Rendus de l Academie des Sciences – Serie iii, Sciences de la Vie. 1998;321:689–697. doi: 10.1016/S0764-4469(98)80009-7. - DOI - PubMed
    1. Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC. The mortality consequences of the continued use of chloroquine in Africa: Experience in Siaya, western Kenya. Am J Trop Med Hyg. 2003;68:386–390. - PubMed
    1. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 2001;17:593–597. doi: 10.1016/S1471-4922(01)02031-1. - DOI - PubMed
    1. International Artemisinin Study Group Artesunate combinations for treating uncomplicated malaria: a prospective individual patient data meta-analysis. Cochrane Database of Systematic Reviews. 2002.

Publication types